CLAIMS:

1. A topical pharmaceutical formulation comprising:

(a) 5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaborole, or a pharmaceutically acceptable salt, or a hydrate or a solvate thereof;

(b) from about 5% (w/w) to about 15% (w/w) propylene glycol;

(c) petrolatum;

(d) a glyceride blend from about 3% (w/w) to about 10% (w/w), wherein the glyceride blend comprises a monoglyceride and a diglyceride;

(e) edetate calcium disodium, from about 0.0001% (w/w) to about 0.01% (w/w); and

(f) a stiffening agent from about 2% (w/w) to about 8% (w/w), wherein the stiffening agent is 5% (w/w) paraffin wax NF.

2. The topical pharmaceutical formulation of claim 1, wherein the formulation comprises no more than about 0.5% (w/w) water.

3. The topical pharmaceutical formulation of claim 2, wherein the amount of the propylene glycol is about 9% (w/w).

4. The topical pharmaceutical formulation of claim 1, wherein the amount of the glyceride blend is about 7% (w/w) and the glyceride blend is Mono- and Di-glyceride NF.

5. The topical pharmaceutical formulation of claim 4, wherein from about 40% (w/w) to about 55% (w/w) of the glyceride blend is a monoglyceride.

6. The topical pharmaceutical formulation of claim 1, wherein the amount of edetate calcium disodium is about 0.0035% (w/w).

7. The topical pharmaceutical formulation of a preceding claim, further comprising an antioxidant from about 0.01% (w/w) to about 1% (w/w) selected from the group consisting of butylated hydroxytoluene, ascorbic acid or a pharmaceutically acceptable salt thereof, ascorbic palmitate, butylated

hydroxyanisole, 2,4,5-trihydroxybutyrophenone, 4-hydroxymethyl-2,6-di-*tert*-butylphenol, erythorbic acid, gum guaiac, propyl gallate, thiodipropionic acid, dilauryl thiodipropionate, tert-butylhydroquinone and tocopherols such as vitamin E, and the like, including pharmaceutically acceptable salts and esters thereof, and mixtures thereof.

8. The topical pharmaceutical formulation of claim 7, wherein the antioxidant is butylated hydroxytoluene.

9. The topical pharmaceutical formulation of claim 7 or 8, wherein the amount of the antioxidant is 0.1% (w/w).

10. Use of the topical pharmaceutical formulation of any one of claims 1-9, in the manufacture of a medicament for treating an inflammatory-related condition in an animal.

11. The use as claimed in claim 10, wherein the inflammatory-related condition is psoriasis.

12**.** The use as claimed in claim 10, wherein the inflammatory-related condition is atopic dermatitis.

13. The use as claimed in claim 12, wherein the animal is a human.

14. The use as claimed in claim 13, wherein the pharmaceutical formulation is to be administered to an affected area of a human on a twice daily basis.

15. The use as claimed in claim 14, wherein the pharmaceutical formulation is to be administered over a period of about 28 days.

16. The use as claimed in claim 13, wherein a second active agent is to be administered in combination with the pharmaceutical formulation.

17. The use as claimed in claim 16, wherein the second active agent is a JAK kinase inhibitor which is Tofacitinib, JTE-052, Baricitinib, or Upadacitinib.

18. The topical pharmaceutical formulation of any one of claims 1-9, for use in therapy.